Low Heparin Molecular Weight — Competitive Intelligence Brief

Low Heparin Molecular Weight (Low Heparin Molecular Weight) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticoagulant. Area: Cardiovascular.

phase 3 Anticoagulant Antithrombin III (indirect inhibitor of Factor Xa and Factor IIa) Cardiovascular Small molecule

Target snapshot

Low Heparin Molecular Weight (Low Heparin Molecular Weight) — University Hospital, Angers. Low molecular weight heparin (LMWH) inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Low Heparin Molecular Weight TARGET	Low Heparin Molecular Weight	University Hospital, Angers	phase 3	Anticoagulant	Antithrombin III (indirect inhibitor of Factor Xa and Factor IIa)
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	marketed	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Coumadin	warfarin	Generic (originally Wisconsin Alumni Research Foundation)	marketed	Vitamin K antagonist (anticoagulant)	Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7	1954-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III, Coagulation Factors Xa and IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III; Coagulation Factors Xa and IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III; Coagulation Factors Xa and IIa	1939-01-01
Heparin Sodium In Plastic Container	Heparin Sodium	Fresenius Kabi	marketed	Anticoagulant	Antithrombin III, Coagulation Factors Xa and IIa	1939-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticoagulant class)

1. Fresenius Kabi · 4 drugs in this class
2. University of Sao Paulo · 3 drugs in this class
3. Beijing Anzhen Hospital · 2 drugs in this class
4. San Filippo Neri General Hospital · 2 drugs in this class
5. Yong Seog Oh · 2 drugs in this class
6. CCRF Consulting Co., Ltd. · 1 drug in this class
7. Boston Scientific Corporation · 1 drug in this class
8. Beijing Suncadia Pharmaceuticals Co., Ltd · 1 drug in this class
9. Faculty Hospital Kralovske Vinohrady · 1 drug in this class
10. Deutsches Herzzentrum Muenchen · 1 drug in this class